EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Strategies to Overcome PD-1/PD-L1 Blockade Resistance: Focusing on Combination with Immune Checkpoint Blockades

Dinglin Liu, Haoyue Xiao, Ying Xiang, Dian Zhong, Yuchen Liu, Yunfei Wang, Weijia Zhang

Journal of Cancer · 24.07.2025 · 16 (11) · 3425-3449

DOI: 10.7150/jca.108163 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cancer, erschienen am 24.07.2025. Verfasst von Dinglin Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434023, China. Die Arbeit wurde bisher 17-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, immune checkpoint blockades (ICBs) have made rapid progress in the field of cancer treatment, providing significant therapeutic effects and survival benefits, especially in patients with advanced refractory tumors. PD-1/PD-L1 blockade is one of the most widely used ICBs. However, its application is limited by low response rate and drug resistance. It is of great significance to investigate the complex mechanisms of PD-1/PD-L1 blockade resistance. In this review, we outline some crucial aspects, including lack of effector T cells, lack of target PD-1/PD-L1, poor immunogenicity of tumors, immunosuppressive TME, and other mechanisms (such as metabolism, epigenetic alterations, and gut microbiota). Combination therapy has become a promising strategy to overcome drug resistance. Based on the upregulation of other immune checkpoints after PD-1/PD-L1 blockade treatment, we focus on the combination with other ICBs, including CTLA-4, TIM-3, LAG-3, TIGIT, VISTA, and some emerging immune checkpoints, so as to provide evidence for improving the benefit of ICBs in cancers.

Schlagwörter

Stichwörter der Autor:innen

PD-1PD-L1combination therapyimmune checkpoint blockaderesistance

Autor:innen und Institutionen

  • Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434023, China.
  • Laboratory of Oncology, Center for Molecular Medicine, School of Basic Medicine, Health Science Center, Yangtze University, 1 Nanhuan Road, Jingzhou, Hubei 434023, China.

Zitieren

APA

Liu, D., Xiao, H., Xiang, Y., Zhong, D., Liu, Y., Wang, Y., & Zhang, W. (2025). Strategies to Overcome PD-1/PD-L1 Blockade Resistance: Focusing on Combination with Immune Checkpoint Blockades. Journal of Cancer, 16(11), 3425-3449. https://doi.org/10.7150/jca.108163

Vancouver

Liu D, Xiao H, Xiang Y, Zhong D, Liu Y, Wang Y, et al. Strategies to Overcome PD-1/PD-L1 Blockade Resistance: Focusing on Combination with Immune Checkpoint Blockades. Journal of Cancer. 2025;16(11):3425-3449. doi:10.7150/jca.108163

BibTeX
@article{Liu2025,
  author = {Liu, Dinglin and Xiao, Haoyue and Xiang, Ying and Zhong, Dian and Liu, Yuchen and Wang, Yunfei and Zhang, Weijia},
  title = {Strategies to Overcome PD-1/PD-L1 Blockade Resistance: Focusing on Combination with Immune Checkpoint Blockades},
  journal = {Journal of Cancer},
  year = {2025},
  volume = {16},
  number = {11},
  pages = {3425--3449},
  doi = {10.7150/jca.108163}
}
Kostenlos starten →